MX2023000438A - Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. - Google Patents

Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.

Info

Publication number
MX2023000438A
MX2023000438A MX2023000438A MX2023000438A MX2023000438A MX 2023000438 A MX2023000438 A MX 2023000438A MX 2023000438 A MX2023000438 A MX 2023000438A MX 2023000438 A MX2023000438 A MX 2023000438A MX 2023000438 A MX2023000438 A MX 2023000438A
Authority
MX
Mexico
Prior art keywords
mcl
inhibitors
indole derivatives
ether containing
containing indole
Prior art date
Application number
MX2023000438A
Other languages
English (en)
Inventor
Petrus Jacobus Johannes Antonius Buijnsters
Frederik Jan Rita Rombouts
Tristan Reuillon
BOECK Benoît Christian Albert Ghislain DE
Aldo Peschiulli
Adriana- Ingrid VELTER
Cabrera Sofia Ferrer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023000438A publication Critical patent/MX2023000438A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
MX2023000438A 2020-07-08 2021-07-08 Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. MX2023000438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184729 2020-07-08
PCT/EP2021/069037 WO2022008674A1 (en) 2020-07-08 2021-07-08 Macrocyclic ether containing indole derivatives as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
MX2023000438A true MX2023000438A (es) 2023-02-09

Family

ID=71833112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000438A MX2023000438A (es) 2020-07-08 2021-07-08 Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.

Country Status (10)

Country Link
US (1) US20230250109A1 (es)
EP (1) EP4178677A1 (es)
JP (1) JP2023532592A (es)
KR (1) KR20230035621A (es)
CN (1) CN115776888A (es)
AU (1) AU2021306644A1 (es)
BR (1) BR112023000212A2 (es)
CA (1) CA3184877A1 (es)
MX (1) MX2023000438A (es)
WO (1) WO2022008674A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012137A (es) 2018-05-14 2021-01-29 Gilead Sciences Inc Inhibidores de mcl-1.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182625A1 (en) 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
AU2019347963A1 (en) 2018-09-30 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2020103864A1 (en) 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors

Also Published As

Publication number Publication date
AU2021306644A1 (en) 2023-03-09
KR20230035621A (ko) 2023-03-14
CN115776888A (zh) 2023-03-10
JP2023532592A (ja) 2023-07-28
BR112023000212A2 (pt) 2023-01-31
US20230250109A1 (en) 2023-08-10
CA3184877A1 (en) 2022-01-13
WO2022008674A1 (en) 2022-01-13
EP4178677A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2023007162A (es) Macrociclos y sus usos.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
MX2022016004A (es) Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1.
MX2022015998A (es) Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.